美国食品和药物管理局审查与减肥药物西马格卢提德和提泽帕提德相关的精神健康报告. FDA reviews mental health reports linked to weight loss drugs semaglutide and tirzepatide.

美国食品和药物管理局正在审查与减肥药物semaglutide和tirzepatide相关的焦虑,抑郁和自杀念头的报告, The FDA is reviewing reports of anxiety, depression, and suicidal thoughts linked to the weight loss drugs semaglutide and tirzepatide, marketed as Wegovy and Zepbound. 一项研究发现,在使用者和非使用者之间没有重大的心理健康得分差异。 A study found no significant mental health score differences between users and non-users. GLP-1药物与心理健康之间的关系很复杂,受血糖水平、营养摄入和生活方式变化等因素的影响。 The relationship between GLP-1 medications and mental health is complex, influenced by factors like blood sugar levels, nutrient intake, and lifestyle changes. 鼓励用户就情绪变化向保健服务提供者咨询。 Users are encouraged to consult healthcare providers about mood changes.